Devices and methods for treating bone tissue

Information

  • Patent Grant
  • 10085783
  • Patent Number
    10,085,783
  • Date Filed
    Thursday, March 14, 2013
    11 years ago
  • Date Issued
    Tuesday, October 2, 2018
    6 years ago
Abstract
The present disclosure relates to devices for injecting material into a body. The devices include a housing having a deployment cannula extending therefrom. The device also includes a rotary drive member wherein rotational movement of the drive member relative to the housing results in linear movement of an elongated injection member within a lumen of and out of a distal end opening of the deployment cannula. The elongated injection member includes a proximal end portion that may have a Tuohy-Huber tip and/or varying radii therealong.
Description
TECHNICAL FIELD

The present disclosure generally relates to devices and methods employed in minimally invasive surgical procedures. More particularly, the present disclosure generally relates to various devices and methods for injecting material into and/or forming channels in a treatment site within a patient, especially into bone including vertebral bone tissue for the treatment of vertebral compression fractures.


BACKGROUND

It is often necessary or desirable to administer, deliver or inject material into a particular target location or zone in the human body for therapeutic or diagnostic treatments or procedures. The injectable material can include a variety of different fluids, including orthopedic cements, bone and other bone augmentation materials, drugs, contrast agents, cell-based treatment materials such as stem cells, and other fluids for a variety of different diagnostic or therapeutic treatments or procedures. Although the subject matter of this disclosure is not limited to orthopedic treatments in general or spinal treatments in particular, treatment of spinal conditions, including treatment of vertebral compression fractures, is an area where injection of a material into the vertebral body is a particularly common treatment.


A vertebral compression fracture (VCF) is a common spinal condition that typically involves the injection of material as part of the treatment. A vertebral compression fracture is a crushing or collapsing injury to one or more vertebrae. Vertebral compression fractures are generally, but not exclusively, associated with osteoporosis, metastasis, and/or trauma. Osteoporosis reduces bone density, thereby weakening bones and predisposing them to fracture. The osteoporosis-weakened vertebrae can collapse during normal activity and are also more vulnerable to injury from shock or other forces acting on the spine. In severe cases of osteoporosis, actions as simple as bending forward can be enough to cause a vertebral compression fracture.


One technique used to treat vertebral compression fractures is injection of a bone augmentation material directly into the fractured vertebral body. This procedure is commonly referred to as vertebroplasty. More particularly, vertebroplasty involves injecting bone augmentation material (for example, bone cement, bone growth agent, allograph material or autograph material) into the collapsed vertebra to stabilize and strengthen the crushed vertebra. Other techniques for treating vertebral compression fractures employ the injection of bone cement into cavities formed within the cancellous bone of a vertebral body. Such cavities may be formed by removal of cancellous bone using cavity/channel creation tools or by compaction of the cancellous bone using expansion of balloons within the vertebral body. Bone cement is also injected in or around implants that are inserted into the vertebral body to separate and support the vertebral endplates.


Injection of bone augmentation material into the vertebral body, however, sometimes carries with it the risk of “extravasation.” For example, in vertebroplasty and certain other procedures, bone augmentation material, and particularly bone cement, is introduced directly into the vertebral body with the physician preferably viewing the cement dispersion via fluoroscopy during the procedure. This type of injection requires particular care as there is a risk of extravasation, which includes undesired leakage or dispersion of the bone augmentation material into undesired areas, such as into the vicinity of the spinal cord or nerves.


Accordingly, although the subject matter described herein is not limited to orthopedic or spinal treatments, it has particular benefits in the treatment of VCF, and is significant because there has been and continues to be a long felt need for devices and methods to control or limit the flow materials during injection into the body and in particular to control and/or limit the flow of bone augmentation material, such as bone cement and related fluids, injected into the vertebral body during vertebroplasty and certain other related VCF treatments.


SUMMARY

There are several aspects of the present subject matter which may be embodied separately or together in the devices and systems described and claimed below. These aspects may be employed alone or in combination with other aspects of the subject matter described herein, and the description of these aspects together is not intended to preclude the use of these aspects separately or the claiming of such aspects separately or in different combinations as set forth in the claims appended hereto.


In one aspect, a device for injecting material into a body includes a housing having proximal and distal end portions. The device also includes a deployment cannula having a proximal end portion, a distal end portion and a lumen that extends from an opening in the proximal end portion of the deployment cannula to an opening in the distal end portion of the deployment cannula. The proximal end portion of the deployment cannula is operatively connected to the distal end portion of the housing. The distal end portion of the deployment cannula is configured for insertion into the body. The device also includes a rotary drive member having a proximal end portion and a distal end portion. The rotary drive member extends through a proximal end opening in the housing wherein rotational movement of the drive member relative to the housing results in distal linear movement of the drive member. The device further includes an elongated injection member for injecting material into the body. The elongated injection member is disposed and moveable within the lumen of the deployment cannula. The elongated injection member has a proximal end portion, a distal end portion and a lumen that extends between an opening in the proximal end portion of the elongated injection member and an opening in the distal end portion of the elongated injection member. The proximal end portion of the elongated injection member is operatively connected to the rotary drive member such that distal linear movement of the drive member advances the elongated injection member distally through the lumen of deployment cannula to extend the distal end portion of the elongated injection member out of the distal end portion opening of the deployment cannula.


In another aspect, the devices of the present disclosure may include a torque limiting member such that the deployment cannula rotates, with certain torque limits, as the housing is rotated. The torque limiting member discontinues transmission of force or releases when a threshold level of torque is encountered.


In another aspect, the devices of the present disclosure may include a force or drive limiting member such that the elongated injection member advances or is driven with certain force limits, as the elongated member penetrates the bone. The force limiting member discontinues drive force to the elongated member or releases when a threshold level of force is encountered.


In yet another aspect, the elongated injection member of the devices of the present disclosure may include a distal end portion that has a Tuohy-Huber tip.


In another aspect, the elongated injection member of the devices of the present disclosure may include a distal end portion having a plurality of differing radii of curvature. The distal end portion having differing radii of curvature may also have a Tuohy-Huber tip.


In a further aspect, a medical needle includes an elongated tubular shaft that has a proximal end portion, a distal end portion and a lumen that extends from an opening in the proximal end portion to an opening in the distal end portion. At least the distal end portion of the elongated shaft has an unconstrained arcuate configuration defined by differing radii of curvature along a curve of the distal end portion of the elongated shaft. The opening in the distal end portion is defined by a flat surface located at a distal tip of the elongated shaft. At least the distal end portion of the cannula being movable between a constrained substantially linear configuration that is constrained by an external constraining force and the arcuate unconstrained configuration, when the external straining force is released.





BRIEF DESCRIPTION OF THE DRAWINGS

In the course of this description, reference will be made to the accompanying drawings, wherein:



FIG. 1 is a perspective view of one embodiment of a material delivery device of the present disclosure;



FIG. 2 is a cross-sectional view of the material delivery device of FIG. 1 with an internal injection member in an advanced position extending from a side opening in a deployment cannula;



FIG. 2A is an exploded view of the material delivery device of FIG. 1;



FIG. 3 is a perspective view of the distal end portion of the material delivery device of FIG. 1 showing an alternative configuration of the distal end portion of the internal elongated injection member extending from a side opening in the distal end portion of the deployment cannula;



FIG. 3A is a side view of the distal end portion of the material delivery device of FIG. 1 showing an alternative configuration of the distal end portion of the elongated injection member extending from a side opening in the distal end portion of the deployment cannula;



FIG. 4 is a perspective view of an alternative configuration of the distal end portion of the deployment cannula of the material delivery device;



FIG. 5 is a perspective view of the material delivery device being inserted through an access cannula and into a vertebral body;



FIG. 6 is a partial enlarged cross-sectional view of one configuration of a torque limiting device that may be employed in the material delivery device of FIG. 1;



FIGS. 7 and 8 are cross-sectional views illustrating the operation of the torque limiting device of FIG. 6;



FIG. 9 is a perspective view of another embodiment of a material delivery device in accordance with the present disclosure;



FIG. 10 is an enlarged cross-sectional view of one configuration of a connector for connecting an injectable material supply to an elongated injection member of the device of FIG. 9;



FIG. 11 is a cross sectional view of the material delivery device of FIG. 9;



FIG. 12 is a cross-sectional view of another embodiment of a material delivery device in accordance with the present disclosure;



FIG. 12A is an exploded view of another embodiment of a material delivery device in accordance with the present disclosure; and



FIGS. 13-16 illustrate a method for treating a vertebral body in accordance with the present disclosure.





Corresponding reference numerals indicate corresponding parts throughout the several views.


DETAILED DESCRIPTION

Although detailed embodiments of the present subject matter are disclosed herein, it is to be understood that the disclosed embodiments are merely exemplary, and the subject matter may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting the subject matter claimed, but merely as examples to illustrate and describe the subject matter and various aspects thereof.


Disclosed herein are devices and methods for forming channels and/or injecting material into a treatment site within a patient. Such treatment sites may include bones and bone tissue. The devices may be particularly useful in treating injured or damaged vertebral bodies, such as those having compression fractures. While the devices are described herein in relation to vertebral bodies, the devices are not limited to such and may be used to treat other tissues and parts of the body as well.



FIGS. 1, 2 and 2A illustrate one embodiment of a material injection device 10 in accordance with the present disclosure. Injection device 10 includes, among other features, a housing 12, a deployment cannula 18, an elongated injection member 28, which also may serve as a channel forming member or bone tamp, (FIG. 2) and a drive member 30, such as a rotary or threaded drive member. As explained in more detail below, the elongated injection member 28 is moveable within deployment cannula 18 and through a distal opening, such as side opening 26, of the deployment cannula 18 wherein the elongated injection 28 may be employed to form a channel(s) through the tissue of the treatment site and/or inject material into a treatment site. The channel(s) may be formed prior to the injection of material or substantially simultaneously with the injection of material. Alternatively, multiple channels may first be formed prior to injection of material and then material may be injected into the multiple channels.


The housing 12 has a proximal end portion 14, a distal end portion 16 and an inner cavity 17 (FIG. 2). Referring to FIGS. 1 and 2A, the housing 12 may include first and second halves or shells 19a/19b which are attached to each other in any suitable manner, such as with screws, adhesive or ultrasonic welding, to form housing 12. As illustrated in FIG. 2A and later in FIGS. 7a and 8, housing halves 19a/19b are shown attached to each other by screws 23.


Deployment cannula 18 is preferably connected to and extends from the distal end portion 16 of housing 12. Deployment cannula 18 includes a proximal end portion 20, a distal end portion 22 and a lumen 21 extending from an opening 24 (FIG. 2) in the proximal end portion 20 to an opening, such as side opening 26, in the distal end portion 22. In the illustrated embodiment, opening 26 in the distal end portion of deployment cannula 18 is a side opening located in a sidewall of the deployment cannula 18. In other embodiments, opening 26 may be located at the distal tip 25 of the deployment cannula 18. Additionally, as better seen in FIG. 4, the distal tip 25 of the deployment cannula 18 may include a sharp point or edges for passing or cutting through tissue as the distal end portion 22 of the deployment cannula 18 is inserted through tissue and into the treatment site. In some applications, instead of using a separate introduction trocar or cannula, the distal tip 25 itself may act as an access stylet or may be used as the access tool that is initially inserted through layers of outer tissue and into the treatment site. In the embodiment illustrated in FIG. 4, the distal tip 25 of the deployment cannula 18 is a multifaceted member that includes edges 27 for cutting through tissue or penetrate through bone.


Turning back to FIGS. 1, 2 and 2A, the proximal end portion 20 of deployment cannula 18 may be connected to housing 12 by a hub 32. In the illustrated embodiment, hub 32 includes a proximal end portion 34 positioned within an opening 36 in the distal end portion 16 of housing 12 and a distal end portion 38 extending from opening 36. The proximal end portion 20 of deployment cannula 18 is connected to hub 32, for example by adhesive or weld based on the material used, and extends through an inner passageway of hub 32 into cavity 17 of housing 12. Deployment cannula 18 and housing 12 may be rotatable or non-rotatable relative to each other. In the illustrated embodiment, deployment cannula 18 and housing 12 are rotatable relative to each other about longitudinal axis A (FIG. 2). In this embodiment, deployment cannula 18 is fixedly connected to hub 32 wherein hub 32 is rotatably mounted to housing 12. A portion 15 of housing 12 adjacent opening 36 projects into a mating channel 33 circumferentially extending around hub 32. The mating between portion 15 of housing 12 and channel 33 of hub 32 connects hub 32 to housing 12 in a fixed axial position while allowing housing 12 to rotate about axis A relative to hub 32. In another configuration, deployment cannula 18 may be rotatably connected to hub 32 which is fixedly connected to housing 12. And in another embodiment, deployment cannula 18 is fixed to hub 32 and hub 32 is fixed to housing 12.


In other configurations, the delivery cannula 18 is connected to the housing 12 such that the delivery cannula 18 rotates about axis A (FIG. 2), within certain torque limits, as housing 12 is rotated thereabout. In such embodiments, the device 10 may include a torque limiting mechanism, such as a torque break-away or clutch, that transmits rotational force from the housing 12 to the delivery cannula 18 until a threshold of rotational resistance is encountered by the delivery cannula 18. At such time, the torque limiting mechanism will release and discontinue transmission of rotational forces from the housing 12 to the delivery cannula 18 and the delivery cannula 18 with remain stationary relative to the patient or surgical site as the housing continues to rotate about axis A. The torque limiting mechanisms reduces the risk of damage to the device and/or trauma to the patient that may occur when undue rotational resistance is encountered in the treatment site. For example and as explained in more detail below, after the distal end portion 22 of delivery cannula 18 is placed within a treatment site, the housing 12 may be rotated to locate the distal end portion 22 of the delivery cannula 18 (e.g., the side opening 26) into a preferred or different position within the treatment site. If the delivery cannula 18 encounters a threshold level of rotational resistance, the torque limiting mechanism will discontinue transmission of torque from the housing 12 to the delivery cannula 18 which will result in the cannula remaining stationary within the treatment site while the housing is allowed to continue to rotate. The torque limiting feature may also prevent damage to the injection device, such as in a situation wherein the injection member 28 has been deployed therefrom. In such applications, undue force during rotation of device 10 into a preferred or different position may develop between the elongated injection member 28 extending from distal opening 26 of the deployment cannula 18 and adjacent bone, for example, and may result in damage to the elongated injection member 28 that could make it difficult to inject and/or retract the elongated injection member 28 back into the deployment cannula 18 and out of the treatment site. With the torque limiter, when the resistance to torque reaches a certain threshold, the torque limiting mechanism releases and discontinues the transmission of torque from the housing 12 to the deployment cannula 18 therefor preventing damage to the device and/or surrounding bone or tissue.


The torque limiting mechanism may be any suitable mechanism for limiting or discontinuing the transmission of torque, such as a shear pin, friction fit, magnetic forces, or ball and detent. The design of the mechanism is meant to limit the peak torque and thus the peak force applied to the elongated injection member 28 in all configurations of deployment such that it remains intact. FIGS. 6-8 illustrate one embodiment of a ball and detent torque limiting mechanism that may be used with any of the devices disclosed herein. The torque limiting mechanism includes a detent surface (such as a notch or recess) located in either the hub 32 or the housing 12 wherein a ball is biased into the detent. The mating between the ball and the detent normally transmits the rotational force from the housing 12 to the hub 32 to rotate the delivery cannula 18 with the housing 12. In the embodiment illustrated in FIGS. 6-8, the proximal portion 34 of hub 32 includes a detent 45 in a sidewall thereof. Housing 12 includes a channel 35 located in an inner wall 37 of the housing 12 wherein a biasing member 39, such as a coiled spring, biases a ball 41 into detent 45. The engagement of ball 41 and detent 45 transmits rotational force from housing 12 to hub 32. When the deployment cannula 18 encounters a certain threshold of rotational resistance that exceeds the biasing force holding the ball 41 in the detent 45, the ball slips out of the detent 45, and the housing 12 is allowed to continue to rotate relative to the hub 32. Thus, the deployment cannula 18 remains stationary within the treatment site as the housing continues to rotate.


Referring back to FIG. 2, elongated injection member 28 is preferably an elongated, hollow tube or shaft, which is at least partially disposed in and movable through the lumen 21 of deployment cannula 18. Elongated injection member 28 includes a proximal end portion 40, a distal end portion 42 and an internal material flow lumen extending from an opening 44 in the proximal end portion 40 to an opening 46 in the distal end portion 42.


Rotary drive member 30, such as a threaded drive screw, is positioned within an opening 48 (which is in communication of cavity 17) in the proximal end portion 14 of housing 12. The threaded drive member 30 includes a proximal end portion 50, a distal end portion 52 and threads 54 that at least partially extend along the length of threaded drive member 30. Housing 12 includes corresponding threads 56, which may be integral with the housing 12 or may be a separate component attached (glued, welded or press-fitted) to housing 12. In the illustrated embodiment, corresponding threads 56 are formed by a nut 58 that is affixed to the housing 12 at or adjacent to the opening 48 in the proximal end portion 14 of the housing 12. When threaded drive member 30 is rotated in one direction, threaded drive member 30 travels, or is otherwise advanced linearly, in a distal direction into the cavity 17 of housing 12. When threaded drive member 30 is rotated in the other direction, threaded drive member 30 travels, or is retracted linearly, in a proximal direction outwardly of opening 48 of housing 12. Threaded drive member 30 may include a gripping member 60, such as a handle or knob, preferably located at the proximal end 50 of the thread drive member 30 such that a user may grip gripping member 60 to more easily rotate the threaded drive member 30.


The proximal end portion 40 of elongated injection member 28 is operably connected to threaded drive member 30. In the illustrated embodiment, the proximal end portion 40 of elongated injection member 28 extends proximally from the proximal end opening 24 of deployment cannula 18 and is connected to rotary drive member 30. More specifically, the proximal end portion 40 of the elongated injection member 28 is rotatably connected to drive member 30 such that when drive member 30 is rotated relative to housing 12 to advance or retract the threaded drive member 30, elongated injection member 28 does not rotate therewith. Elongated injection member 28 does, however, travel linearly in the proximal and distal directions with the drive member 30. Thus, when the drive member 30 is rotated in one direction, the elongated injection member 28 travels or is advanced linearly in the proximal direction relative to housing 12 and deployment cannula 18. When the drive member 30 is rotated in the other direction, the elongated injection member 28 travels or is retracted linearly in the proximal direction.


Comparing FIGS. 1 and 2, as rotary drive member 30 is rotated so as to distally advance the drive member 30 into inner cavity 17 of the housing 12, the drive member 30 distally advances the elongated injection member 28 through the lumen 21 of deployment cannula 18 and out of distal opening 26 of the deployment cannula 18. The pitch size of threads 54 of the illustrated drive member 30 directly affects or determines the distance or amount of linear travel (i.e., distal advancement and proximal retraction) of the drive member 30 and elongated injection member 28 connected thereto that takes place upon each increment of rotation of the drive member 30. As such, rotation of the drive member 30 provides for controlled, selected incremental, continuous, and/or fine advancement of the elongated injection member 28 out of the distal end opening 26 of the deployment cannula 18 and into the treatment site. As a result, the operator of device 10 may selectively advance and retract the distal end portion 42 of the elongated injection member 28 into and from the treatment site. The pitch size of the threads 54 may vary along the length of the threaded drive member 30 or may vary between devices, depending on the desired application.


In the embodiment illustrated in FIG. 2, the proximal end portion 40 of the elongated injection member 28 preferably extends through drive member 30 and includes a portion 62 that extends proximally past the proximal end portion 50 of drive member 30. Portion 62 of elongated injection member 28 is operably connected to an injectable material-receiving port 64. Port 64 includes a distal end portion 66 having a distal end opening 68, which opening 68 may be operatively connected to and receive portion 62 of the elongated injection member 28 so that proximal end opening 44 of the elongated injection member 28 is in fluid communication with passageway 74 of port 64. Port 64 also includes a proximal end 70 having a proximal end opening 72 wherein passageway 74 extends from proximal opening 72 to distal end opening 68. Proximal end 70 is configured to be connected to a supply of injectable material. In one embodiment, proximal end portion 70 defines or includes a luer-type connector. The injectable material includes but is not limited to, bone filler, bone augmentation material, bone cement, autograph, allograph, osteoconductive materials, therapeutic materials, genetic materials, cells, contrast agents, and/or drugs. The material supply may be, any suitable source for injecting material under pressure, such as, for example, a syringe containing material, such as the screw type syringe 111 shown in FIG. 11. Such material may be injected from the supply of injectable material through the port 64 and into the lumen of the elongated injection member 28. The material travels through the lumen of the elongated injection member 28 and exits through the opening 46 in the distal end portion 42 of the elongated injection member 28 into the treatment site.


In one alternative, the material-receiving injection port 64 is a rotatable luer connector wherein proximal end portion 70 and distal end portion 66 rotate relative to one another. This allows the device 10 to be rotated without the need for rotating the supply of injectable material.


Referring to FIGS. 2-3A, at least the distal end portion 42 of the elongated injection member 28 has a generally arcuate configuration when extending from distal opening 26 of the deployment cannula 18. In one embodiment, the distal end portion 42 of the elongated injection member 28 has an initial generally arcuate unconstrained configuration which is moveable i.e., deformable, into a substantially straight constrained configuration when an external constraint is placed on the distal end portion 42 of the elongated injection member 28. “Substantially straight” includes some variation or undulation and is not limited to completely straight. The distal end portion 42 of elongated injection member 28 is then moveable back to the generally arcuate unconstrained configuration when the constraint is removed. For instance, at least the distal end portion 42 of the elongated injection member 28 has an initial unconstrained arcuate configuration, such as the configurations illustrated in FIGS. 2-3A and 13. The distal end portion 42 of the elongated injection member 28 is inserted into the lumen 21 of deployment cannula 18 which deployment cannula 18 constrains the distal end portion 42 into a substantially straight or linear configuration for passage through the lumen 21 of the deployment cannula 18. Upon exiting out of the distal end opening 26 of the deployment cannula 28, the cannula constraint is removed and the distal end portion 42 of the elongated injection member 28 returns to its initial or similar arcuate configuration. In other words, at least the distal end portion 42 of the elongated injection member 28 is moveable or changeable from a substantially straight or linear configuration for passage through the deployment cannula 18 to a non-straight configuration, such as the curved or arcuate configurations illustrated in FIGS. 2-3A, upon exiting distal end opening 26 of the deployment cannula 18.


Movement of the elongated injection member 28 between the substantially straight configuration and the generally arcuate configuration may be achieved in any variety of ways, including but not limited to use of shape memory materials, a plurality of layers of material, varying thickness of the material, incorporation of a tensioning member, slotting, cutting, or pre-setting the shape of the material or any combination of the above. Additionally, the length or extent of curvature of the distal end portion 42 of the elongated injection 28 member may be different depending on the desired application. For example, the distal end portion may have only a small amount of curvature or extend to a full circle or coil or to a plurality of helical or spiral coils. More specifically, the arcuate or curved distal end portion 42 may extend to form a generally arc-shaped portion (e.g., a generally 45°, 90° or 180° or 270° or up to 360° arc), or may extend in a circular-shape or spiral-shape substantially lying in a single plane or extending in a helical shape, with a vertical extent extending through several different planes. As used herein, the term “spiral” refers to a coil-shaped structure that lies within a single plane, while the term “helical” refers to a coil-shaped structure that has a three-dimensional component or does not lie in one plane.



FIGS. 3 and 3A illustrate exemplary configurations of the distal end portion 42 of elongated injection member 28 that have reduced or anti-coring features, which features may be used alone or in combination in any of the injection devices disclosed herein. It is known that when the distal end portion of a needle or hollow tube or shaft is inserted into tissue, there may be a tendency for the distal opening to core tissue. Such coring may not be desirable in certain applications and the cored tissue may undesirably clog the lumen of the needle, tube or shaft. In one example of the present subject matter, referring first to FIG. 3, the distal end portion 42 of the elongated injection member 28 preferably resists coring, and extends from opening 26 of the deployment cannula 18 in a generally arcuate configuration. The distal tip 43 of the elongated injection member 28 includes an opening 46 which opens in a generally radial direction inwardly of the curved configuration of the distal end portion 42 of elongated injection member 28. In the illustrated embodiment elongated injection member 28 includes a Tuohy-Huber type tip and opening. Such Tuohy-Huber type tips are shown and described in U.S. Pat. No. 2,409,979 to Huber, hereby incorporated by reference. Generally, distal tip 43 is a curved tip that includes a flat beveled or inclined surface 76 that defines the opening 46, which opening 46 opens in a generally radial direction inwardly of the curved configuration of the distal end portion 42 of elongated injection member 28. The surface 76 is substantially flat and lies at an angle relative to the axis of tubular elongated injection member 28. The distal tip 43 may, but does not necessarily, come to a sharp point for piercing tissue. As mentioned above, one of the advantages of employing the Tuohy-Huber type tip is that is tends to reduce coring of tissue during insertion of the elongated injection member 28 into treatment site for forming channels and/or injecting materials. Specifically, as the distal end portion 42 of the elongated injection element 28 exits opening 26 of the deployment cannula 18 and curves, the opening 46 in the Tuohy-Huber type tip 43 faces radially inwardly which acts to somewhat shield the opening 46 and assists in preventing the opening 46 from coring tissue.


Turning now to FIG. 3A, the distal end portion 42 of the elongated injection member 28 may include sections having different radii of curvature. For example, a more distal section 78 of the distal end portion 42 may have a tighter or smaller radius of curvature R than a more immediately adjacent proximal section 80 of the distal end portion 42. In the illustrated embodiment, section 78 of the distal end portion 42 of elongated injection member 28 may have a radius of curvature R which is smaller than the radius of curvature R′ of the proximally adjacent section 80. The smaller or tighter radius of curvature of section 78 directs opening 46 more inwardly relative to the curvature of the distal end portion 42 of the elongated injection member 28, which further assists in preventing coring of tissue as the elongated injection member 28 is inserted into the treatment site. In another embodiment, an obturator can be inserted inside elongated injecting member 28 to close opening 46 while it is inserted into the treatment site for injecting material and/or creating channels. The obturator may be retrieve prior to bone cement injection (not shown). When the distal end portion 42 is formed from the shape memory material Nitinol, the varying radii of the distal end portion 42 can be formed during the shape setting process. The shape setting process may include the use of progressive shape setting cycles with dies having progressively tighter (smaller) radius features. In another embodiment, the shape setting may include a single die or die like feature setting the shape of the distal end portion 42.


In one embodiment, the distal end portion 42 of the elongated injection member 28 includes both a Tuohy-Huber type tip and a distal section of distal end portion 42 has a tighter or smaller radius of curvature than an immediate adjacent proximal section of the distal end portion 42. The combination of the Tuohy-Huber tip and the tighter radius of curvature of the distal section orientates the distal opening 46 of the elongated injection member 28 inwardly to assist in the prevention of coring material as the elongated injection member 28 is inserted into the treatment site.


The elongated injection member may be made of different materials. For example, when the distal end portion 42 of the elongated injection member 28 is made from a shape memory material, such as Nitinol, the proximal end portion 40 of elongated injection member 28 may be made of a different material, such as stainless steel. A distal end portion 42 made of a shape memory metal may be joined to a proximal end portion 40 of the same or other material by any suitable manner, such as by soldering or brazing. In another alternative structure, a Nitinol tube defining the distal end portion 42 may be press fitted to a stainless steel tube defining the proximal end portion 40. Such a press fitting processes may take place in low temperatures so as to cool the Nitinol material to its martensitic phase. In one embodiment, dry ice or a low temperature compressed gas can be used to cool the Nitinol tube. While in the martensitic phase the material is more malleable and can be easily press fitted to the stainless steel tube. When the Nitinol temperature returns to room temperature, the Nitinol returns to its superelastic phase, creating a strong radial lap joint. In another process, the stainless steel to may be swaged and thus yielded while the Nitinol remains in the super elastic phase. Swaging creates a strong radial lap joint between the two tubes.



FIG. 5 shows the deployment cannula 18 of device 10 being inserted into a vertebral body 82 through an access member, such as access cannula 84. The access cannula 84 includes a proximal end portion 90, a distal end portion 92 and a lumen extending therethrough. A handle 88 is located at the proximal end portion 90 of access cannula 84. The distal end portion 92 of the access cannula 84 is introduced into a treatment site for gaining access to the treatment site. The distal end portion 92 of access cannula 84 can be introduced into a treatment site by any suitable methods which may include the use of Jamshidi needles, stylets, trocars, dilators and the like.


The access cannula 84 or handle 88 may include indicators or markings thereon to indicate to the operator the orientation of the tools inserted therethrough or to align the tools in a desired orientation within the treatment site. Such indicators may include visual marks 94 on the handle 88 or marks on the access cannula 84. Device 10 may also include indicators or markers that indicate the orientation of the device 10 within the treatment site. For example, the device 10 may include visual indicators 11 indicating the location of opening 26 and/or the trajectory of the elongated injection member 28 as it exits the distal opening 26 of the deployment cannula 18. During the treatment of vertebral bodies, such alignment may be useful wherein a channel creating device has been inserted through the access cannula 84 and into the interior region of the vertebral body to form channels within the cancellous bone of the vertebral body prior to insertion of device 10. After the channel creation device has been withdrawn from the access cannula 84, device 10 is inserted therethrough and the indicators 11 on the device 10 and indicators 94 on handle 88 may be aligned to orient device 10 and the distal end portion 42 of elongated injection member 28 in a desired orientation relative to the channels created by the channel creation device. In another embodiment, device 10 is used to first create channels and then the channels are re-cannulated later to deliver the injectable materials created previously by device 10. In another embodiment device 10 may be used as a standalone device to create a channel and then inject bone cement into the channel before a second or multiple channels are created.



FIGS. 9-11 illustrate another embodiment of an injection device 110 of the present disclosure. The injection device 110 is similar to injection device 10 in several aspects, including having a housing 112, a deployment cannula 118 and an elongated injection member 128. Referring to FIG. 11, the proximal end portion 140 of elongated injection member 128 may be operatively connected to the supply of injectable material 113 through an L-shaped connector 129. The L-shaped connector 129 includes a first portion 131 that is located within cavity 117 defined by housing 112 and a second portion 133 extending out of housing 112 through a slot 135 in the wall of housing 112. The first portion 131 of L-shaped connector is operably connected to the proximal end portion 140 of the elongated injection member 128. The second portion 133 of the L-shaped connector 129 extending through slot 135 of the housing 112 is operably connectable to a supply of injectable material 113 such as syringe. The second portion 133 of the L-shaped connector may include for example, a luer-type connector at a terminal end 115 thereof. A proximal portion or surface 137 of the L-shaped connector 129 is engaged by the distal end portion 152 of the rotary drive member 130 such that the L-shaped connector 129 and the elongated injection member 128 connected thereto moves proximally and distally with the rotary drive member 130.



FIG. 10 illustrates one embodiment of the L-shaped connector 129, the L-shaped connector 129 may include a first compression sleeve 139 on the leg of the L that is attached to the proximal end portion 140 of the elongated injection member 128 and a second compression sleeve 141 that is on the upright portion of the L connector and is attached to an injectable material receiving port 151. The first compression sleeve 139 and the second compression sleeve 141 may be attached to one another by a threaded connection, press fit or weld. The proximal end portion 140 of the elongated injection member 128 may include a radially extending flange portion 143 that abuts a tapered inner wall 145 of the first compression sleeve 139. Furthermore, the L-shaped connector 129 may include a retaining member, such as a crush washer 147, located in the first compression sleeve 139. The crush washer 147 forces the flange portion 143 of the elongated injection member 128 against inner tapered wall 145 to create a seal therewith. The crush washer 147 may apply a sufficient force to form a seal therebetween but still allow the elongated injection member 128 to rotate relative to the L-shaped connector 129.


As shown in FIGS. 10 and 11, the proximal portion 137 of the L-shaped connector 129 is rotatably connected to the distal end portion 152 of the rotary drive member 130 such that the rotary drive member 130 may rotate relative to the L-shaped connector 129, but the L-shaped connector 129 travels linearly in the proximal and distal direction with the rotary drive member 130 in cavity 117 of housing 112. As the L-shaped connector 129 moves proximally and distally within cavity 117, the second portion 133 of the L-shaped connector 129 moves proximally and distally within slot 135 in the wall of housing 112. The supply of injectable material 113 may include a syringe 111 that is in operable communication with L-shaped connector 129. In the illustrated embodiment syringe 111 is connected to L-shaped connector 129 through tubing 153 and 155. In other embodiments the end 157 of syringe 111 may be directly connected to L-shaped connector 129. The syringe 111 may be, for example, a plunger or screw type syringe. A shut off valve 161 may be located between tubing 153 and 155 to allow or stop flow of material from syringe 111 to device 110.


In one method of delivering injectable material to a treatment site, the shut off valve 161 can be used to create back pressure within syringe 111 that can be used to flow injectable material through device 110. For instance, the injector screw 159 of the injection syringe 111 can be turned to flow injectable material into the device 110 in order to prime the elongated injection member 128 with injectable material. The valve 161 can then be closed off to stop flow of injectable material into the elongated injection member 128. The deployment cannula 118 can be positioned within a treatment site and the distal end portion 142 of the elongated injection member 128 can be partially or fully advanced into the treatment site. With the valve 161 remaining in the closed position, the injector screw 159 can be turned to build up pressure within the syringe 111. The valve 161 may then be opened and the elongated injection member 118 can be advanced or retracted as the back pressure pushes a bolus of material injected under such pressure through the elongated injection member 128 and into the treatment site.



FIG. 12 illustrates another embodiment of an injection device 210 in accordance with the present disclosure. Injection device 210 has similar features to that of the previously described devices including having a housing 212, a deployment cannula 218 and an elongated injection member 228. In the embodiment of FIG. 12, the injectable material receiving port includes a Y-connector 264 having a first port 263 and a second port 265. The first and second ports 263 and 265 may both be used to receive injectable materials. Alternatively, the first or second ports 263 and 265 may receive a plunger or obturator 267 that is inserted into the lumen of the elongated injection member 228 to expel or remove clogs or unwanted materials therefrom. For example, the lumen of the elongated injection member 228 may become clogged with tissue or injectable material during use. When this happens, the plunger 267 may be inserted through the port 265 of the Y-connector 264 and into the lumen where the plunger contacts and breaks up the clog. The plunger 267 in FIG. 12 is not shown to size. The plunger 267 may have sufficient length to extend along the entire length of elongated injection member 228, partially along injection member 228 or out of the distal end portion of injection member 228. When injection member 228 serves or acts as a channel creation device or bone tamp, the plunger 267 may extend to and be substantially coextensive with the distal opening of injection member 228. The plunger 267 may be sufficiently flexible to be introduced through connector 264 and into the lumen of elongated injection member 228 but sufficiently rigid to unclog blockages within the lumen of elongated injection member 228. In the illustrated embodiment, the plunger 267 is connected to a screw on cap 269 that screws on to second port 265. Alternatively, plunger 267 may be insertion through the port 263 so as to optimize the column strength of an obturator through a straight path rather than a curved path. Furthermore, a plunger 267 may be employed with any of the embodiments described herein. In the injection device only includes a single port, the plunger and material source may be interchanged, as required by the particular application.



FIG. 12A illustrates another embodiment of a material delivery device 310 which includes several features similar to those of the material delivery devices described above, including shells 319a/319b that are attached to each other by screws 323 to form a housing, a deployment cannula 318, an elongated injection member 328, a drive member 330, a gripping member 360 and a material receiving port 364. In device 310, the torque limiting mechanism between the housing and the delivery cannula 318 has a different configuration than that described above. Additionally, device 310 includes a drive limiting mechanism associated with the drive member 330 that disconnects drive force to the drive member 330 if a threshold level of insertion resistance is encountered during distal advancement and insertion of the elongated injection member 328 into the treatment site. Such drive limiting mechanisms associated with the drive member may be incorporated into any of the material injection devices disclosed herein. Additionally, the configuration of the torque limiting mechanism between the housing and delivery cannula may also be incorporated into any of the material delivery devices disclosed herein.


Turning first to the drive limiting mechanism, such mechanism may be any suitable drive limiting mechanism that limits or discontinues transmission of drive force to the drive member. For example, the drive limiting mechanism may be a torque limiting mechanism, such as a shear pin, magnetic forces, friction fit, or ball and detent. FIG. 12A illustrates one example of drive limiting mechanism which includes a ball and detent torque limiting mechanism between gripping member 360 and drive member 330. The torque limiting mechanism limits or discontinues the transmission of drive force from gripping member 360 to drive member 330 when a threshold level of insertion resistance is encountered during insertion of the elongated material injection member 328 into the treatment site. The torque limiting mechanism reduces the risk of tissue injury and damage to the device when a threshold lever of insertion resistance is encountered.


The torque limiting mechanism includes a detent surface (such as a notch or recess) associated with either the gripping member 360 or the drive member 330 wherein a ball is biased into the detent. The mating between the ball and the detent normally transmits the rotational force from the gripping member 360 to the drive member 330 to rotate the drive member 330. In the embodiment illustrated in FIG. 12A, the proximal end portion 350 of drive member 330 includes a detent 380 on an outer surface thereof. The gripping member 360 includes a biasing member 382, such as a coiled spring, associated therewith. The biasing member 382 biases a ball 384 into detent 380. The engagement of ball 384 and detent 380 transmits rotational force from gripping member 360 to drive member 330 which advances elongated injection member 328 through deployment cannula 318 and into the treatment site. If the elongated injection member 328 encounters a certain threshold of resistance to insertion that exceeds the biasing force holding the ball 384 in the detent 380, the ball 384 slips out of the detent 380, and the gripping member 360 is allowed to continue to rotate while the drive member 330 remains stationary relative to the housing, thereby discontinuing advancement of the elongated injection member 328. The drive limiting mechanism is preferably reengageable so that the drive member 330 may be rotated in the opposite direction to retract the elongated injection member 328 from the treatment site. In the illustrated embodiment, the ball 384 is reengaged with the detent 380 by continued rotation of the gripping member 360 relative to the drive member 330 to realign the ball 384 with the detent 380. After reengagement of the drive limiting mechanism, the gripping member 360 may be rotated in the opposite direction to retract the drive member 330 proximally which results in retraction of the elongated injection member 328 from the treatment site.


Turning now to the torque limiting mechanism between the deployment cannula 328 and housing illustrated in FIG. 12A, the proximal end portion 334 of hub 332 includes a hollow cylinder or sleeve in which drive member 330 is disposed when the device 310 is assembled. The torque limiting mechanism is similar to that describe above and may be any suitable torque limiting mechanism that transmits rotational force between the housing and deployment cannula 328 until a threshold level of torque resistance is encountered. In the illustrated embodiment, the torque limiting mechanism is located between the cylindrical proximal end portion 334 and the housing. The torque limiting mechanism includes a detent surface (such as a notch or recess) located in either the proximal end portion 334 of the hub 32 or the housing, wherein a ball is biased into the detent. The mating between the ball and the detent normally transmits the rotational force from the housing to the hub 332 to rotate the delivery cannula 318 with the housing 12. In illustrated embodiment, the proximal portion 334 of hub 332 includes a detent 333 in a sidewall thereof. The housing includes a biasing member 339 associated therewith, such as a coiled spring, that biases a ball 341 into detent 333. Similar to the torque limiting mechanisms described above with respect to FIGS. 6-8, the housing may include a channel in an inner wall thereof wherein the biasing member 339 is disposed within the channel and biases ball 341 into detent 333. The engagement of ball 341 and detent 333 transmits rotational force from the housing to the hub 332. When the deployment cannula 318 encounters a certain threshold of rotational resistance that exceeds the biasing force holding the ball 341 in the detent 333, the ball slips out of the detent, and the housing is allowed to continue to rotate relative to the hub 332. Thus, the deployment cannula 318 remains stationary within the treatment site as the housing continues to rotate.


Also in this embodiment, the cylindrical proximal end portion of the hub 332 includes a proximal surface 331 that may contact nut 358 to hold nut 358 in position within the housing as the drive member 330 is rotated within the cylindrical proximal end portion 334 of hub 332 during advancement or retraction of the drive member 330.


Depending on the application, the features of the devices disclosed in FIGS. 1, 11, 12 and 12A may be combined with each other and/or combined with any other features disclosed herein.



FIGS. 13-15 illustrate one embodiment of a method of treating a bone such as a vertebral body with the injection devices disclosed herein. Referring to FIG. 13, the distal end portion 92 of access cannula 84, optionally, may be inserted into the interior region 300 of a vertebral body 302. When the distal end tip 25 of deployment cannula 18 includes an introducer tip for insertion through tissue and into the treatment site, as illustrated in FIG. 4, an access cannula is not required. When an access cannula is present, the distal end portion 22 of the delivery cannula 18 of device 10 is inserted through the access cannula 84 and into the vertebral body 302. The operator may use, if present, any indicators included on the access cannula 84 and/or the device 10 to orient the distal end portion 22 of the delivery cannula 18 in the desired direction and to determine the trajectory of the distal end portion 42 of the elongated injection member 28 as it exits from the deployment cannula 18. Once the deployment cannula 18 is in the desired position within the treatment site, the elongated injection member 28 in a substantially linear configuration is advanced distally through the deployment cannula 18 and out of the opening 26 in the distal end thereof to form channels within the bone of the vertebral body and/or to position the elongated injection member 28 for injection of injectable material within the vertebral body.


As the distal end portion 42 of the elongated injection member 28 is advanced out of the distal end opening 26 of the deployment cannula 18, it inherently or by mechanical assistance curves into a generally arcuate configuration as described above. As also described above, the distal end portion 42 of the elongated injection member 28 may, optionally, include a Tuohy-Huber type tip and/or varying radii therealong to substantially reduce coring of the tissue by the distal opening 46 of the elongated injection member 28 as it is inserted into the treatment site. Alternatively or in combination with the Tuohy-Huber type tip or varying radii, an obturator may be present within lumen of the injection member 28, as described above with respect to FIG. 12, to prevent tissue or other debris from entering the injection member as it is inserted into the treatment site.


Depending on the application, injectable material 304 may be, optionally, injected into the treatment site through the elongated injection member 28 as the distal end portion 42 thereof exits the distal end portion 22 of the delivery cannula 18. Alternatively, the elongated injection member 28 may be used to create a channel within the tissue, such as cancellous bone tissue, and then the injectable material may be injected through the elongated injection member 28 into the channel and/or surrounding tissue after the distal end portion 22 has been retracted from the thus formed channel or as the distal end portion 22 is being retracted from the thus formed channel. If an obturator is used during insertion of the elongated injection member 28 into the tissue for channel creation or injecting injectable material, the obturator is removed from the elongated injection member 28 prior to injection of the injectable material.


Depending on the procedure the operator may desire to rotate deployment cannula 18 while the distal end portion 42 of the elongated injection member 28 is extended therefrom to “sweep” the elongated injection member 28 through tissue in the treatment site. In such procedures, the device 10 may include the above-described torque limiting mechanism between the housing and the deployment cannula 18 that discontinues transmission of rotational forces from the housing 12 to the deployment cannula 18 when a threshold level of rotational resistance is met.


Referring to FIG. 14, the elongated injection member 28 is retracted back into deployment cannula 18. As the elongated injection member 28 is retracted, the injectable material 304 may be, optionally, continually or intermittently injected through the elongated injection member 28 and into the treatment site. The elongated injection member 28 returns to the substantially linear configuration as it is retracted back into deployment cannula 18. In FIG. 15, the elongated injection member 28 has been fully retracted into the deployment cannula 18, leaving injectable material 304 within the vertebral body to reinforce the vertebral body against further fracture.


Turning to FIG. 16, if desired, the deployment cannula 18 may, after a first injection of material, be rotated a desired amount within access cannula 84 so that the elongated injection member 28 may be deployed in different directions. When present, indicators on the access cannula 84 and/or housing 12 of device 10 may be used to reposition the deployment cannula 18 in a desired orientation, after which injectable material may be injected into the treatment site as described above with regards to FIGS. 13-15. Repositioning and injecting material may be repeated as many times and in as many directions as desired for a given procedure.


In another embodiments, the elongated injection member 28 may be employed to first create multiple channels within the bone tissue by repositioning the elongated injection member in different orientations within the treatment site. After the desired number of channels has been created, the elongated injection is then used to injection injectable material into the multiple channels. As discussed above, if an obturator is located within the elongated injection member 28 during the creation of the channels, the obturator is removed from the elongated injection member 28 prior to injection of the injectable material.


It will be understood that the embodiments described above are illustrative of some of the applications of the principles of the present subject matter. Numerous modifications may be made by those skilled in the art without departing from the spirit and scope of the claimed subject matter, including those combinations of features that are individually disclosed or claimed herein. For these reasons, the scope hereof is not limited to the above description but is as set forth in the following claims, and it is understood that claims may be directed to the features hereof, including as combinations of features that are individually disclosed or claimed herein.

Claims
  • 1. A device for injecting material into a body, comprising: a housing having proximal and distal end portions;an elongated deployment cannula having a proximal end portion, a distal end portion and a longitudinal axis, the elongated deployment cannula also including a lumen extending axially within the cannula from an opening in the proximal end portion of the elongated deployment cannula to an opening in the distal end portion of the elongated deployment cannula, the proximal end portion of the elongated deployment cannula being operatively connected to the distal end portion of the housing, and the distal end portion of the elongated deployment cannula being configured for insertion into the body;a rotary drive member having a proximal end portion and a distal end portion with a threaded section extending axially therealong, the rotary drive member extending through a proximal end opening in the housing with the threaded section being at least partially disposed within the housing wherein the housing includes a corresponding threaded section in operative engagement with the threaded section of the rotary drive member and whereby rotational movement of the rotary drive member relative to the housing results in linear movement of the rotary drive member substantially along the longitudinal axis of the deployment cannula;an elongated injection member for injecting material into the body, the elongated injection member being disposed and moveable within the lumen of the deployment cannula, the elongated injection member having a proximal end portion, a distal end portion and a lumen extending between an opening in the proximal end portion of the elongated injection member and an opening in the distal end portion of the elongated injection member, the proximal end portion of the elongated injection member being rotatably connected to the rotary drive member such that when the rotary drive member is rotated relative to the housing, the elongated injection member does not rotate with the drive member and distal linear movement of the rotary drive member advances the elongated injection member distally through the lumen of the deployment cannula to extend the distal end portion of the elongated injection member out of the distal end portion opening of the deployment cannula; anda material inlet port in communication with the lumen of the elongated injection member and configured for connection to a material source, the rotary drive member being rotatable relative to the material inlet port.
  • 2. The device of claim 1 wherein at least the distal end portion of the elongated injection member has a first generally linear configuration while disposed within the lumen of the deployment cannula.
  • 3. The device of claim 2 wherein at least the distal end portion of the elongated injection member when extending out from the distal end portion opening of the deployment cannula has a second generally non-linear configuration.
  • 4. The device of claim 3 wherein the second generally non-linear configuration comprises an arcuate configuration.
  • 5. The device of claim 4 wherein the elongated injection member is generally cylindrically shaped tubular member and the distal end portion opening of the elongated injection member is defined by a substantially flat inclined surface at a distal tip of elongated injection member.
  • 6. The device of claim 4 wherein the elongated injection member comprises a Tuohy-Huber needle.
  • 7. The device of claim 4 wherein the arcuate configuration is defined by a plurality of differing radii of curvature.
  • 8. The device of claim 7 wherein a proximal section of the distal end portion has a larger radius of curvature than a more distal section of the distal end portion.
  • 9. The device of claim 1 wherein the proximal end portion of the elongated injection member extends through the rotary drive member.
  • 10. The device of claim 1 further including an injectable material source coupled to the material inlet port.
  • 11. The device of claim 1 wherein a grippable portion is located at the proximal end portion of the rotary drive member.
  • 12. The device of claim 1 wherein the deployment cannula and the housing are rotatable relative to one another.
  • 13. The device of claim 12 comprising a torque limiter operably connected between the deployment cannula and the housing.
  • 14. The device of claim 13 in which the torque limiter includes a torque disconnect clutch that disconnects a transfer of torque from the housing to the deployment cannula when the torque reaches a selected threshold.
  • 15. The device of claim 14 wherein the torque disconnect clutch comprises a detent associated with one of the deployment cannula and the housing and a biased detent-engaging member associated with the other of the deployment cannula and the housing, wherein the detent slips past the detent engaging member when the torque reaches the selected threshold.
  • 16. The device of claim 1 wherein the housing and/or the deployment cannula includes a visual indicator indicating a trajectory of the distal end portion of the elongated injection member when the distal end portion of the elongated injection member extends from the distal end portion opening of the deployment cannula.
  • 17. The device of claim 1 wherein a distal tip of the deployment cannula includes a tissue piercing member.
  • 18. The device of claim 1 further including an access cannula adapted for insertion into the body, the deployment cannula being advanceable through the access cannula and into the body, and the access cannula having visual markers for aligning the position of the deployment cannula within the body.
  • 19. The device of claim 1 further including a torque limiter associated with the rotary drive member, wherein the torque limiter discontinues drive forces to the drive member when a threshold of resistance is encountered.
US Referenced Citations (803)
Number Name Date Kind
1965653 Kennedy Jul 1934 A
3091237 Skinner May 1963 A
3112743 Cochran et al. Dec 1963 A
3648294 Shahrestani Mar 1972 A
3800788 White Apr 1974 A
3867728 Stubstad et al. Feb 1975 A
3875595 Froning Apr 1975 A
3889685 Ling et al. Jun 1975 A
3964480 Fronlng Jun 1976 A
4262676 Jamshidi Apr 1981 A
4274183 Malcom et al. Aug 1981 A
4312337 Donohue Jan 1982 A
4313434 Segal Feb 1982 A
4399814 Pratt, Jr. et al. Aug 1983 A
4462394 Jacobs Jul 1984 A
4458435 Murray Aug 1984 A
4487479 Brody Aug 1984 A
4488549 Lee et al. Dec 1984 A
4562598 Kranz Jan 1986 A
4595006 Burke et al. Jun 1986 A
4625722 Murray Dec 1986 A
4627434 Murray Dec 1986 A
4628945 Johnson, Jr. Dec 1986 A
4630616 Tretinyak Dec 1986 A
4665906 Jervis May 1987 A
4686973 Frisch Aug 1987 A
4697584 Haynes Oct 1987 A
4706670 Andersen et al. Nov 1987 A
4714478 Fischer Dec 1987 A
4743256 Brantigan May 1988 A
4772287 Ray et al. Sep 1988 A
4834069 Umeda May 1989 A
4838282 Strasser et al. Jun 1989 A
4863476 Shepperd Sep 1989 A
4878915 Brantigan Nov 1989 A
4888022 Huebsch Dec 1989 A
4888024 Powlan Dec 1989 A
4892550 Huebsch Jan 1990 A
4896662 Noble Jan 1990 A
4898577 Badger et al. Feb 1990 A
4904261 Dove et al. Feb 1990 A
4941466 Romano Jul 1990 A
4961740 Ray et al. Oct 1990 A
4969888 Scholten et al. Nov 1990 A
5015247 Michelson May 1991 A
5015255 Kusllch May 1991 A
5051189 Farrah Sep 1991 A
5053035 McLaren Oct 1991 A
5055104 Ray Oct 1991 A
5059193 Kuslich Oct 1991 A
5071435 Fuchs et al. Dec 1991 A
5098435 Stednitz et al. Mar 1992 A
5102413 Poddar Apr 1992 A
5108404 Scholten et al. Apr 1992 A
5119044 Hoedlmayr et al. Jun 1992 A
5122130 Keller Jun 1992 A
5123926 Pisharodi Jun 1992 A
5147365 Arroyo et al. Sep 1992 A
5163989 Campbell et al. Nov 1992 A
5171280 Baumgartner Dec 1992 A
5176663 Kimsey et al. Jan 1993 A
5176692 Wilk et al. Jan 1993 A
5183052 Terwilliger Feb 1993 A
5192327 Brantigan Mar 1993 A
5228441 Lundquist Jul 1993 A
5242448 Pettine et al. Sep 1993 A
5242879 Abe et al. Sep 1993 A
5257632 Turkel et al. Nov 1993 A
5263953 Bagby Nov 1993 A
5285795 Ryan et al. Feb 1994 A
5303718 Krajicek Apr 1994 A
5306308 Gross et al. Apr 1994 A
5306310 Siebels Apr 1994 A
5322505 Krause et al. Jun 1994 A
5330429 Noguchi et al. Jul 1994 A
5331975 Bonutti Jul 1994 A
5361752 Moll et al. Nov 1994 A
5383932 Wilson et al. Jan 1995 A
5385151 Scarfone et al. Jan 1995 A
5423816 Lin Jun 1995 A
5423817 Lin Jun 1995 A
5423850 Berger Jun 1995 A
5431658 Moskovich Jul 1995 A
5441538 Bonutti Aug 1995 A
5454365 Bonutti Oct 1995 A
5454827 Aust et al. Oct 1995 A
5456686 Klapper Oct 1995 A
5462563 Shearer et al. Oct 1995 A
5468245 Vargas, III Nov 1995 A
5480400 Berger Jan 1996 A
5484437 Michelson Jan 1996 A
5509923 Middleman et al. Apr 1996 A
5514143 Bonutti et al. May 1996 A
5514153 Bonutti Jun 1996 A
5522398 Goldenberg et al. Jun 1996 A
5522790 Moll et al. Jun 1996 A
5522848 Bonutti Jun 1996 A
5527343 Bonutti Jun 1996 A
5527624 Higgins et al. Jun 1996 A
5531856 Moll et al. Jul 1996 A
5534023 Henley Jul 1996 A
5538009 Byrne et al. Jul 1996 A
5540711 Kieturakis et al. Jul 1996 A
5545222 Bonutti Aug 1996 A
5549679 Kuslich Aug 1996 A
5562736 Ray et al. Oct 1996 A
5571109 Bertagnoli Nov 1996 A
5571189 Kuslich Nov 1996 A
5571190 Ulrich et al. Nov 1996 A
5575790 Chen et al. Nov 1996 A
5593409 Michelson Jan 1997 A
5601556 Pisharodi Feb 1997 A
5601572 Middleman et al. Feb 1997 A
5632746 Middleman et al. May 1997 A
5645597 Krapiva Jul 1997 A
5665122 Karabin Sep 1997 A
5674295 Ray et al. Oct 1997 A
5681263 Flesch Oct 1997 A
5693100 Pisharodi Dec 1997 A
5695513 Johnson et al. Dec 1997 A
5700239 Yoon Dec 1997 A
5702453 Rabbe et al. Dec 1997 A
5702454 Baumgartner Dec 1997 A
5716416 Lin Feb 1998 A
5741253 Michelson Apr 1998 A
5749679 Middleman et al. May 1998 A
5755797 Baumgartner May 1998 A
5756127 Grisoni et al. May 1998 A
5766252 Henry Jun 1998 A
5772661 Michelson Jun 1998 A
5782832 Larsen et al. Jul 1998 A
5788703 Mittelmeier et al. Aug 1998 A
5807275 Jamshidi Sep 1998 A
5820628 Middleman et al. Oct 1998 A
5823979 Mezo Oct 1998 A
5824093 Ray et al. Oct 1998 A
5827289 Reiley et al. Oct 1998 A
5836948 Zucherman et al. Nov 1998 A
5843017 Yoon Dec 1998 A
5848986 Lundquist et al. Dec 1998 A
5851212 Zirps et al. Dec 1998 A
5860977 Zucherman et al. Jan 1999 A
5865848 Baker Feb 1999 A
5871470 McWha Feb 1999 A
5904690 Middleman et al. May 1999 A
5919235 Husson Jul 1999 A
5925074 Gingras et al. Jul 1999 A
5961554 Janson et al. Oct 1999 A
5972015 Scribner et al. Oct 1999 A
5976186 Bao et al. Nov 1999 A
5980522 Koros et al. Nov 1999 A
6012494 Balazs Jan 2000 A
6015436 Schonhoffer Jan 2000 A
6019793 Perren et al. Feb 2000 A
6030401 Marino Feb 2000 A
6033406 Mathews Mar 2000 A
6033412 Losken et al. Mar 2000 A
6039740 Olerud Mar 2000 A
6039761 Li Mar 2000 A
6045552 Zucherman et al. Apr 2000 A
6048342 Zucherman et al. Apr 2000 A
6048346 Reiley et al. Apr 2000 A
6048360 Khosravi et al. Apr 2000 A
6066154 Reiley et al. May 2000 A
6068630 Zucherman et al. May 2000 A
6073051 Sharkey et al. Jun 2000 A
6083226 Winslow et al. Jul 2000 A
6090143 Meriwether et al. Jul 2000 A
6096080 Nicholson Aug 2000 A
6102950 Vaccaro Aug 2000 A
6110210 Norton et al. Aug 2000 A
6113640 Tormala et al. Sep 2000 A
6123705 Michelson Sep 2000 A
6126660 Dietz Oct 2000 A
6127597 Beyar et al. Oct 2000 A
6159211 Boriani et al. Dec 2000 A
6159244 Suddaby Dec 2000 A
6165218 Husson et al. Dec 2000 A
6174337 Keenan Jan 2001 B1
6179873 Zientek Jan 2001 B1
6187048 Milner et al. Feb 2001 B1
6190414 Young et al. Feb 2001 B1
6193757 Foley et al. Feb 2001 B1
6197033 Hald, Jr. et al. Mar 2001 B1
D439980 Reiley et al. Apr 2001 S
6217579 Koros Apr 2001 B1
6221082 Marino et al. Apr 2001 B1
6224603 Marino May 2001 B1
6235030 Zucherman et al. May 2001 B1
6235043 Reiley et al. May 2001 B1
6238491 Davidson et al. May 2001 B1
6241734 Scribner et al. Jun 2001 B1
6248110 Reiley et al. Jun 2001 B1
6251140 Marino et al. Jun 2001 B1
6261289 Levy Jul 2001 B1
6261763 Castro Jul 2001 B1
6264695 Stoy Jul 2001 B1
6280456 Scribner et al. Aug 2001 B1
6280475 Bao et al. Aug 2001 B1
6290724 Marino Sep 2001 B1
D449691 Relley et al. Oct 2001 S
6296647 Robioneck et al. Oct 2001 B1
6312443 Stone Nov 2001 B1
6364828 Yeung et al. Apr 2002 B1
6368325 McKinley et al. Apr 2002 B1
6387130 Stone et al. May 2002 B1
6402750 Atkinson et al. Jun 2002 B1
6419641 Mark et al. Jul 2002 B1
6419705 Erickson Jul 2002 B1
6423071 Lawson Jul 2002 B1
6423083 Reiley et al. Jul 2002 B2
6423089 Gingras et al. Jul 2002 B1
6425887 McGuckin et al. Jul 2002 B1
6425919 Lambrecht Jul 2002 B1
6428541 Boyd et al. Aug 2002 B1
6436140 Liu et al. Aug 2002 B1
6440138 Reiley et al. Aug 2002 B1
6451019 Zucherman et al. Sep 2002 B1
6468279 Reo Oct 2002 B1
6432235 Lambrecht et al. Nov 2002 B1
6478805 Marino et al. Nov 2002 B1
6485518 Cornwall et al. Nov 2002 B1
D467657 Scribner Dec 2002 S
6488710 Besselink Dec 2002 B2
6491626 Stone et al. Dec 2002 B1
6491695 Roggenbuck Dec 2002 B1
6491826 Stone et al. Dec 2002 B1
6498421 Oh Dec 2002 B1
6500178 Zucherman et al. Dec 2002 B2
6500205 Michelson Dec 2002 B1
6508839 Lambrecht et al. Jan 2003 B1
6511471 Rosenman et al. Jan 2003 B2
6612958 Swoyer et al. Jan 2003 B2
D469871 Sand Feb 2003 S
6520991 Huene Feb 2003 B2
D472323 Sand Mar 2003 S
6530930 Marino et al. Mar 2003 B1
6533791 Betz et al. Mar 2003 B1
6533797 Stone et al. Mar 2003 B1
6540747 Marino Apr 2003 B1
6554833 Levy et al. Apr 2003 B2
6558390 Cragg May 2003 B2
6562074 Gerbec et al. May 2003 B2
6572593 Daum Jun 2003 B1
6575919 Reiley et al. Jun 2003 B1
6575979 Cragg Jun 2003 B1
6576016 Hochshuler et al. Jun 2003 B1
6579291 Keith et al. Jun 2003 B1
6582431 Ray Jun 2003 B1
6582433 Yun Jun 2003 B2
6592559 Pakter et al. Jul 2003 B1
6595998 Johnson et al. Jul 2003 B2
6602293 Biermann et al. Aug 2003 B1
6607530 Carl et al. Aug 2003 B1
6607544 Boucher et al. Aug 2003 B1
6610094 Husson Aug 2003 B2
6613054 Scribner et al. Sep 2003 B2
6620190 Trieu Sep 2003 B1
6620196 Trieu Sep 2003 B1
6623505 Scribner et al. Sep 2003 B2
D482787 Reiss Nov 2003 S
6641587 Scribner et al. Nov 2003 B2
6645213 Sand et al. Nov 2003 B2
6648917 Gerbec et al. Nov 2003 B2
D483495 Sand Dec 2003 S
6656178 Veidhuizen et al. Dec 2003 B1
6656180 Stahurski Dec 2003 B2
6660037 Husson et al. Dec 2003 B1
6663647 Reiley et al. Dec 2003 B2
6666890 Michelson Dec 2003 B2
6666891 Boehm, Jr. et al. Dec 2003 B2
6676663 Higueras et al. Jan 2004 B2
6676665 Foley et al. Jan 2004 B2
6682561 Songer et al. Jan 2004 B2
6685742 Jackson Feb 2004 B1
6689125 Keith et al. Feb 2004 B1
6689168 Lleberman Feb 2004 B2
6692563 Zimmermann Feb 2004 B2
6706070 Wagner et al. Mar 2004 B1
6710216 Boucher et al. Apr 2004 B1
6716247 Michelson Apr 2004 B2
6716957 Tunc Apr 2004 B2
6719761 Reiley et al. Apr 2004 B1
6719773 Boucher et al. Apr 2004 B1
6723128 Uk Apr 2004 B2
6726691 Osorio et al. Apr 2004 B2
D490159 Sand May 2004 S
6740093 Hochschuler et al. May 2004 B2
D492032 Muller et al. Jun 2004 S
6749560 Konstorum et al. Jun 2004 B1
6755841 Fraser et al. Jun 2004 B2
D492775 Doelling et al. Jul 2004 S
D493533 Blain Jul 2004 S
6758673 Fromovich et al. Jul 2004 B2
6764514 Li et al. Jul 2004 B1
D495417 Doelling et al. Aug 2004 S
6773460 Jackson Aug 2004 B2
6780151 Grabover et al. Aug 2004 B2
6783530 Levy Aug 2004 B1
6793679 Michelson Sep 2004 B2
6796983 Zucherman et al. Sep 2004 B1
6805695 Keith et al. Oct 2004 B2
6805697 Helm et al. Oct 2004 B1
6808537 Michelson Oct 2004 B2
6814736 Reiley et al. Nov 2004 B2
6814756 Michelson Nov 2004 B1
6821298 Jackson Nov 2004 B1
6830589 Erickson Dec 2004 B2
6835205 Atkinson et al. Dec 2004 B2
6835206 Jackson Dec 2004 B2
6840944 Suddaby Jan 2005 B2
6852126 Ahlgren Feb 2005 B2
6852129 Gerbec et al. Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6863672 Reiley et al. Mar 2005 B2
6863673 Gerbec et al. Mar 2005 B2
6866682 An et al. Mar 2005 B1
6875219 Arramon et al. Apr 2005 B2
6881228 Zdeblick et al. Apr 2005 B2
6883520 Lambrecht et al. Apr 2005 B2
6887248 McKinley et al. May 2005 B2
6893466 Trieu May 2005 B2
6899716 Cragg May 2005 B2
6899719 Reiley et al. May 2005 B2
D506828 Layne et al. Jun 2005 S
6905512 Paes et al. Jun 2005 B2
6908506 Zimmermann Jun 2005 B2
6921403 Cragg et al. Jul 2005 B2
6923810 Michelson Aug 2005 B1
6923813 Phillips et al. Aug 2005 B2
6923814 Hildebrand et al. Aug 2005 B1
6929647 Cohen Aug 2005 B2
6946973 Bray Sep 2005 B1
6952129 Lin et al. Oct 2005 B2
6962606 Michelson Nov 2005 B2
6964674 Matsuura et al. Nov 2005 B1
D512506 Layne et al. Dec 2005 S
6972035 Michelson Dec 2005 B2
6974479 Trieu Dec 2005 B2
6979341 Scribner et al. Dec 2005 B2
6981981 Reiley et al. Jan 2006 B2
6997929 Manzi et al. Feb 2006 B2
7004945 Boyd et al. Feb 2006 B2
7008453 Michelson Mar 2006 B1
7014633 Cragg Mar 2006 B2
7018089 Wenz et al. Mar 2006 B2
7018415 McKay Mar 2006 B1
7018453 Klein et al. Mar 2006 B2
7029498 Boehm et al. Apr 2006 B2
7044954 Relley et al. May 2006 B2
7048694 Mark et al. May 2006 B2
7063703 Reo Jun 2006 B2
7066961 Michelson Jun 2006 B2
7069087 Sharkey et al. Jun 2006 B2
7070598 Lim et al. Jul 2006 B2
7074226 Roehm, III et al. Jul 2006 B2
7081120 Li et al. Jul 2006 B2
7081122 Reiley et al. Jul 2006 B1
7087055 Lim et al. Aug 2006 B2
7094257 Mujwid et al. Aug 2006 B2
7115128 Michelson Oct 2006 B2
7115163 Zimmermann Oct 2006 B2
7118579 Michelson Oct 2006 B2
7118580 Beyersdorff et al. Oct 2006 B1
7118598 Michelson Oct 2006 B2
7124761 Lambrecht et al. Oct 2006 B2
7128760 Michelson Oct 2006 B2
7135424 Worley et al. Nov 2006 B2
7153304 Robie et al. Dec 2006 B2
7153305 Johnson Dec 2006 B2
7153306 Ralph et al. Dec 2006 B2
7153307 Scribner et al. Dec 2006 B2
7156874 Paponneau et al. Jan 2007 B2
7156875 Michelson Jan 2007 B2
7166107 Anderson Jan 2007 B2
7179293 McKay Feb 2007 B2
7189242 Boyd et al. Mar 2007 B2
7204851 Trieu et al. Apr 2007 B2
7207991 Michelson Apr 2007 B2
7211112 Baynham et al. May 2007 B2
7214227 Colleran et al. May 2007 B2
7220281 Lambrecht et al. May 2007 B2
7223227 Pflueger May 2007 B2
7226481 Kuslich Jun 2007 B2
7241297 Shaolian et al. Jul 2007 B2
7244273 Pedersen et al. Jul 2007 B2
7250060 Trieu Jul 2007 B2
7242671 Scribner et al. Aug 2007 B2
7267687 McGuckin Sep 2007 B2
7270679 Istephanous et al. Sep 2007 B2
7276062 McDaniel et al. Oct 2007 B2
7311713 Johnson et al. Dec 2007 B2
7316679 Bierman Jan 2008 B2
7316714 Gordon et al. Jan 2008 B2
7318840 McKay Jan 2008 B2
7320689 Keller Jan 2008 B2
7322962 Forrest Jan 2008 B2
7383639 Malandain Jun 2008 B2
7485134 Simonson Feb 2009 B2
7608083 Lee et al. Oct 2009 B2
7637905 Saadat et al. Dec 2009 B2
7713273 Krueger et al. May 2010 B2
7799035 Krueger et al. Sep 2010 B2
7828807 LeHuec et al. Nov 2010 B2
8057544 Schaller Nov 2011 B2
8128633 Linderman et al. Mar 2012 B2
8187327 Edldin et al. May 2012 B2
8236029 Siegal Aug 2012 B2
D669168 Krueger et al. Oct 2012 S
8529576 Krueger et al. Sep 2013 B2
20010011174 Reiley et al. Aug 2001 A1
20010016741 Burkus et al. Aug 2001 A1
20010049531 Reiley Dec 2001 A1
20020016583 Cragg Feb 2002 A1
20020026195 Layne et al. Feb 2002 A1
20020026244 Trieu Feb 2002 A1
20020045942 Ham Apr 2002 A1
20020068974 Kuslich et al. Jun 2002 A1
20020077700 Varga et al. Jun 2002 A1
20020082584 Rosenman et al. Jun 2002 A1
20020082608 Reiley et al. Jun 2002 A1
20020087163 Dixon et al. Jul 2002 A1
20020091390 Michelson Jul 2002 A1
20020099385 Ralph et al. Jul 2002 A1
20020107519 Dixon et al. Aug 2002 A1
20020107573 Steinberg Aug 2002 A1
20020120238 McGuckin, Jr. Aug 2002 A1
20020156482 Scribner et al. Oct 2002 A1
20020169471 Ferdinand Nov 2002 A1
20020172851 Corey et al. Nov 2002 A1
20020173796 Cragg Nov 2002 A1
20020173841 Ortiz et al. Nov 2002 A1
20020173851 McKay Nov 2002 A1
20020183761 Johnson Dec 2002 A1
20020183778 Relley et al. Dec 2002 A1
20020191457 Sand Dec 2002 A1
20030018390 Husson Jan 2003 A1
20030032963 Reiss et al. Feb 2003 A1
20030050644 Boucher et al. Mar 2003 A1
20030069593 Tremulls et al. Apr 2003 A1
20030074075 Thomas, Jr. Apr 2003 A1
20030108588 Chen et al. Jun 2003 A1
20030130664 Boucher Jul 2003 A1
20030171812 Grunberg et al. Sep 2003 A1
20030191414 Reiley et al. Oct 2003 A1
20030191489 Reiley et al. Oct 2003 A1
20030195518 Cragg Oct 2003 A1
20030195547 Scribner et al. Oct 2003 A1
20030195630 Ferree Oct 2003 A1
20030199979 McGuckin, Jr. Oct 2003 A1
20030203136 Takeuchi Oct 2003 A1
20030220648 Osorio et al. Nov 2003 A1
20030220695 Sevrain Nov 2003 A1
20030229372 Reiley et al. Dec 2003 A1
20030233096 Osorio et al. Dec 2003 A1
20030233146 Grinberg Dec 2003 A1
20040010251 Pitaru et al. Jan 2004 A1
20040010260 Scribner et al. Jan 2004 A1
20040010263 Boucher et al. Jan 2004 A1
20040019354 Johnson et al. Jan 2004 A1
20040024408 Burkus et al. Feb 2004 A1
20040024409 Sand et al. Feb 2004 A1
20040024463 Thomas, Jr. et al. Feb 2004 A1
20040024465 Lambrecht et al. Feb 2004 A1
20040034343 Gillespie et al. Feb 2004 A1
20040034429 Lambrecht et al. Feb 2004 A1
20040049203 Scribner et al. Mar 2004 A1
20040059333 Carl Mar 2004 A1
20040059339 Roehm, III et al. Mar 2004 A1
20040059418 McKay et al. Mar 2004 A1
20040032953 Petit Apr 2004 A1
20040064144 Johnson Apr 2004 A1
20040073308 Kusllch et al. Apr 2004 A1
20040087947 Lim et al. May 2004 A1
20040092933 Shaolian et al. May 2004 A1
20040092948 Stevens et al. May 2004 A1
20040092988 Shaolian et al. May 2004 A1
20040097924 Lambrecht et al. May 2004 A1
20040097930 Justis et al. May 2004 A1
20040097932 Ray, III et al. May 2004 A1
20040098131 Bryan et al. May 2004 A1
20040102774 Trieu May 2004 A1
20040106940 Shaolian et al. Jun 2004 A1
20040111161 Trieu Jun 2004 A1
20040117019 Trieu et al. Jun 2004 A1
20040133124 Bates et al. Jul 2004 A1
20040133229 Lambrecht et al. Jul 2004 A1
20040133280 Trieu Jul 2004 A1
20040138748 Boyer, II et al. Jul 2004 A1
20040153064 Foley et al. Aug 2004 A1
20040153115 Reiley et al. Aug 2004 A1
20040158206 Aboul-Hosn et al. Aug 2004 A1
20040167561 Boucher et al. Aug 2004 A1
20040167562 Osorio et al. Aug 2004 A1
20040167625 Beyar et al. Aug 2004 A1
20040176775 Burkus et al. Sep 2004 A1
20040186471 Trieu Sep 2004 A1
20040186528 Ries et al. Sep 2004 A1
20040186573 Ferree Sep 2004 A1
20040210231 Boucher et al. Oct 2004 A1
20040210310 Trieu Oct 2004 A1
20040215344 Hochschuler et al. Oct 2004 A1
20040220580 Johnson et al. Nov 2004 A1
20040220672 Shadduck Nov 2004 A1
20040225296 Reiss et al. Nov 2004 A1
20040225361 Glenn Nov 2004 A1
20040230191 Frey et al. Nov 2004 A1
20040230309 DiMauro Nov 2004 A1
20040243229 Vidlund et al. Dec 2004 A1
20040243241 Istephanous Dec 2004 A1
20040249377 Kaes et al. Dec 2004 A1
20040254520 Porteous et al. Dec 2004 A1
20040254644 Taylor Dec 2004 A1
20040260300 Gorensek et al. Dec 2004 A1
20040260397 Lambrecht et al. Dec 2004 A1
20040267271 Scribner et al. Dec 2004 A9
20050004578 Lambrecht et al. Jan 2005 A1
20050010293 Zucherman et al. Jan 2005 A1
20050010298 Zucherman et al. Jan 2005 A1
20050015148 Jansen et al. Jan 2005 A1
20050015152 Sweeney Jan 2005 A1
20050021041 Michelson Jan 2005 A1
20050033295 Wisnewski Feb 2005 A1
20050033440 Lambrecht et al. Feb 2005 A1
20050038517 Carrison Feb 2005 A1
20050043737 Reiley et al. Feb 2005 A1
20050043796 Grant et al. Feb 2005 A1
20050054948 Goldenberg Mar 2005 A1
20050055097 Grunberg et al. Mar 2005 A1
20050060036 Schultz et al. Mar 2005 A1
20050060038 Lambrecht et al. Mar 2005 A1
20050065519 Michelson Mar 2005 A1
20050065609 Wardlaw Mar 2005 A1
20050069571 Slivka et al. Mar 2005 A1
20050070908 Cragg Mar 2005 A1
20050070911 Carrison Mar 2005 A1
20050070913 Milbocker et al. Mar 2005 A1
20050071011 Ralph et al. Mar 2005 A1
20050080488 Schultz Apr 2005 A1
20050085912 Amin et al. Apr 2005 A1
20050090833 DiPoto Apr 2005 A1
20050090852 Layne et al. Apr 2005 A1
20050090899 DiPoto Apr 2005 A1
20050107880 Shimp et al. May 2005 A1
20050113918 Messerll et al. May 2005 A1
20050113919 Cragg et al. May 2005 A1
20050113928 Cragg et al. May 2005 A1
20050118228 Trieu Jun 2005 A1
20050119662 Reiley et al. Jun 2005 A1
20050119750 Studer Jun 2005 A1
20050119751 Lawson Jun 2005 A1
20050119752 Williams et al. Jun 2005 A1
20050119754 Trieu et al. Jun 2005 A1
20050124989 Suddaby Jun 2005 A1
20050124992 Ferree Jun 2005 A1
20050124999 Teitelbaum et al. Jun 2005 A1
20050125002 Baran Jun 2005 A1
20050125066 McAfee Jun 2005 A1
20050131267 Talmadge Jun 2005 A1
20050131268 Talmadge Jun 2005 A1
20050131269 Talmadge Jun 2005 A1
20050131536 Eisermann et al. Jun 2005 A1
20050131540 Trieu Jun 2005 A1
20050131541 Trieu Jun 2005 A1
20050137602 Assell et al. Jun 2005 A1
20050142211 Wenz Jun 2005 A1
20050143763 Ortiz et al. Jun 2005 A1
20050143827 Globerman et al. Jun 2005 A1
20050149022 Shaolian et al. Jul 2005 A1
20050149191 Cragg et al. Jul 2005 A1
20050149194 Ahlgren Jul 2005 A1
20050149197 Cauthen Jul 2005 A1
20050154396 Foley et al. Jul 2005 A1
20050154483 Trieu Jul 2005 A1
20050165406 Assell et al. Jul 2005 A1
20050171539 Braun et al. Aug 2005 A1
20050171552 Johnson et al. Aug 2005 A1
20050182412 Johnson et al. Aug 2005 A1
20050182413 Johnson et al. Aug 2005 A1
20050182414 Manzi et al. Aug 2005 A1
20050187556 Stack et al. Aug 2005 A1
20050187558 Johnson et al. Aug 2005 A1
20050187559 Raymond et al. Aug 2005 A1
20050187564 Jayaraman Aug 2005 A1
20050197707 Trieu et al. Sep 2005 A1
20050216018 Sennett Sep 2005 A1
20050216087 Zucherman et al. Sep 2005 A1
20050222684 Ferree Oct 2005 A1
20050228383 Zucherman et al. Oct 2005 A1
20050228391 Levy et al. Oct 2005 A1
20050228397 Malandain et al. Oct 2005 A1
20050234425 Miller et al. Oct 2005 A1
20050234451 Markworth Oct 2005 A1
20050234452 Malandain Oct 2005 A1
20050234456 Malandain Oct 2005 A1
20050240182 Zucherman et al. Oct 2005 A1
20050240189 Rousseau et al. Oct 2005 A1
20050240193 Layne et al. Oct 2005 A1
20050240269 Lambrecht et al. Oct 2005 A1
20050251149 Wenz Nov 2005 A1
20050251260 Gerber et al. Nov 2005 A1
20050261684 Shaolian et al. Nov 2005 A1
20050261695 Cragg et al. Nov 2005 A1
20050261781 Sennett et al. Nov 2005 A1
20050267471 Biedermann Dec 2005 A1
20050273166 Sweeney Dec 2005 A1
20050273173 Gordon Dec 2005 A1
20050278023 Zwirkoskl Dec 2005 A1
20050278027 Hyde, Jr Dec 2005 A1
20050278029 Trieu Dec 2005 A1
20050283244 Gordon et al. Dec 2005 A1
20050287071 Wenz Dec 2005 A1
20060004456 McKay Jan 2006 A1
20060009779 Collins et al. Jan 2006 A1
20060030850 Keegan et al. Feb 2006 A1
20060030933 DeLegge Feb 2006 A1
20060030943 Peterman Feb 2006 A1
20060036241 Siegal Feb 2006 A1
20060036259 Carl et al. Feb 2006 A1
20060036261 McDonnell Feb 2006 A1
20060036273 Siegal Feb 2006 A1
20060041258 Galea Feb 2006 A1
20060045904 Aronson Mar 2006 A1
20060058807 Landry et al. Mar 2006 A1
20060058880 Wysockl et al. Mar 2006 A1
20060064171 Trieu Mar 2006 A1
20060069439 Zucherman et al. Mar 2006 A1
20060085002 Trieu et al. Apr 2006 A1
20060085009 Truckai et al. Apr 2006 A1
20060089440 Zucherman et al. Apr 2006 A1
20060089642 Diaz et al. Apr 2006 A1
20060089646 Bonutti Apr 2006 A1
20060089654 Lins et al. Apr 2006 A1
20060089715 Truckai et al. Apr 2006 A1
20060089718 Zucherman et al. Apr 2006 A1
20060089719 Trieu Apr 2006 A1
20060095045 Trieu May 2006 A1
20060095046 Trieu et al. May 2006 A1
20060095134 Trieu et al. May 2006 A1
20060095138 Truckai et al. May 2006 A1
20060100706 Shadduck et al. May 2006 A1
20060106397 Lins May 2006 A1
20060106459 Truckal et al. May 2006 A1
20060122704 Vresilovic et al. Jun 2006 A1
20060129244 Ensign Jun 2006 A1
20060136064 Sherman Jun 2006 A1
20060142858 Colleran et al. Jun 2006 A1
20060142864 Cauthen Jun 2006 A1
20060149136 Seto et al. Jul 2006 A1
20060149237 Markworth et al. Jul 2006 A1
20060149238 Truckaie Jul 2006 A1
20060149252 Markworth et al. Jul 2006 A1
20060149380 Lotz et al. Jul 2006 A1
20060149397 Kuslich et al. Jul 2006 A1
20060155379 Heneveld, Sr. et al. Jul 2006 A1
20060161162 Lambrecht et al. Jul 2006 A1
20060161166 Johnson et al. Jul 2006 A1
20060167553 Cauthen, III et al. Jul 2006 A1
20060173545 Cauthen, III et al. Aug 2006 A1
20060178746 Bartish, Jr. et al. Aug 2006 A1
20060184192 Markworth et al. Aug 2006 A1
20060184247 Edidin et al. Aug 2006 A1
20060184248 Edidin et al. Aug 2006 A1
20060189999 Zwirkoski Aug 2006 A1
20060190083 Arnln et al. Aug 2006 A1
20060190085 Cauthen Aug 2006 A1
20060195102 Malandain Aug 2006 A1
20060195191 Sweeney, II et al. Aug 2006 A1
20060200139 Michelson Sep 2006 A1
20060200164 Michelson Sep 2006 A1
20060200239 Rothman et al. Sep 2006 A1
20060200240 Rothman et al. Sep 2006 A1
20060200241 Rothman et al. Sep 2006 A1
20060200242 Rothman et al. Sep 2006 A1
20060200243 Rothman et al. Sep 2006 A1
20060206116 Yeung Sep 2006 A1
20060206207 Dryer et al. Sep 2006 A1
20060235423 Cantu Oct 2006 A1
20060235521 Zucherman et al. Oct 2006 A1
20060241663 Rice et al. Oct 2006 A1
20060241770 Rhoda et al. Oct 2006 A1
20060247770 Peterman Nov 2006 A1
20060247771 Peterman et al. Nov 2006 A1
20060247781 Francis Nov 2006 A1
20060264896 Palmer Nov 2006 A1
20060264939 Zucherman et al. Nov 2006 A1
20060264945 Edidin et al. Nov 2006 A1
20060265067 Zucherman et al. Nov 2006 A1
20060265077 Zwirkoski Nov 2006 A1
20060271049 Zucherman et al. Nov 2006 A1
20060271061 Beyar et al. Nov 2006 A1
20060276897 Winslow Dec 2006 A1
20060276899 Zipnick et al. Dec 2006 A1
20060282167 Lambrecht et al. Dec 2006 A1
20060287726 Segal et al. Dec 2006 A1
20060287727 Segal Dec 2006 A1
20060293662 Boyer, II et al. Dec 2006 A1
20060293753 Thramann Dec 2006 A1
20070006692 Phan Jan 2007 A1
20070010716 Malandain et al. Jan 2007 A1
20070010717 Cragg Jan 2007 A1
20070010824 Malandain et al. Jan 2007 A1
20070010844 Gong et al. Jan 2007 A1
20070010845 Gong et al. Jan 2007 A1
20070010846 Leung et al. Jan 2007 A1
20070010848 Leung et al. Jan 2007 A1
20070010889 Francis Jan 2007 A1
20070032703 Sankaran et al. Feb 2007 A1
20070032791 Greenhalgh Feb 2007 A1
20070043361 Malandain et al. Feb 2007 A1
20070043362 Malandain et al. Feb 2007 A1
20070043363 Malandain et al. Feb 2007 A1
20070048382 Meyer et al. Mar 2007 A1
20070049849 Schwardt et al. Mar 2007 A1
20070049934 Edidin et al. Mar 2007 A1
20070049935 Edidin et al. Mar 2007 A1
20070050034 Schwardt et al. Mar 2007 A1
20070050035 Schwardt et al. Mar 2007 A1
20070055201 Seto et al. Mar 2007 A1
20070055237 Edidin et al. Mar 2007 A1
20070055246 Zucherman et al. Mar 2007 A1
20070055265 Schaller Mar 2007 A1
20070055266 Osorio et al. Mar 2007 A1
20070055267 Osorio et al. Mar 2007 A1
20070055271 Schaller Mar 2007 A1
20070055272 Schaller Mar 2007 A1
20070055273 Schaller Mar 2007 A1
20070055274 Appenzeller et al. Mar 2007 A1
20070055275 Schaller Mar 2007 A1
20070055276 Edidin Mar 2007 A1
20070055277 Osorio et al. Mar 2007 A1
20070055278 Osorio et al. Mar 2007 A1
20070055281 Osorio et al. Mar 2007 A1
20070055284 Osorio et al. Mar 2007 A1
20070055300 Osorio et al. Mar 2007 A1
20070060933 Sankaran et al. Mar 2007 A1
20070060935 Schwardt et al. Mar 2007 A1
20070067034 Chirico et al. Mar 2007 A1
20070068329 Phan et al. Mar 2007 A1
20070073292 Kohm et al. Mar 2007 A1
20070093689 Steinberg Mar 2007 A1
20070093906 Hudgins et al. Mar 2007 A1
20070078436 Leung et al. Apr 2007 A1
20070078463 Malandain Apr 2007 A1
20070093899 Dutoit et al. Apr 2007 A1
20070123986 Schaller May 2007 A1
20070135922 Trieu Jun 2007 A1
20070149978 Shezifi et al. Jun 2007 A1
20070150059 Ruberte et al. Jun 2007 A1
20070150060 Trieu Jun 2007 A1
20070150061 Trieu Jun 2007 A1
20070150063 Ruberte et al. Jun 2007 A1
20070150064 Ruberte et al. Jun 2007 A1
20070162127 Peterman et al. Jul 2007 A1
20070167945 Lange et al. Jul 2007 A1
20070168038 Trieu Jul 2007 A1
20070173939 Kim Jul 2007 A1
20070179612 Johnson et al. Aug 2007 A1
20070179615 Heinz et al. Aug 2007 A1
20070179616 Braddock, Jr. et al. Aug 2007 A1
20070179618 Trieu et al. Aug 2007 A1
20070185578 O'Neil et al. Aug 2007 A1
20070191953 Trieu Aug 2007 A1
20070197935 Reiley et al. Aug 2007 A1
20070198023 Sand et al. Aug 2007 A1
20070198025 Trieu et al. Aug 2007 A1
20070208426 Trieu Sep 2007 A1
20070213717 Trieu et al. Sep 2007 A1
20070219634 Greenhalgh et al. Sep 2007 A1
20070233074 Anderson et al. Oct 2007 A1
20070260255 Haddock et al. Nov 2007 A1
20070270957 Heinz Nov 2007 A1
20070282443 Globerman et al. Dec 2007 A1
20080021557 Trieu Jan 2008 A1
20080027437 Johnson et al. Jan 2008 A1
20080027453 Johnson et al. Jan 2008 A1
20080027454 Johnson et al. Jan 2008 A1
20080051897 Lopez et al. Feb 2008 A1
20080071356 Greenhalgh et al. Mar 2008 A1
20080097611 Mastrorio et al. Apr 2008 A1
20080125865 Abdelgany May 2008 A1
20080140207 Olmos et al. Jun 2008 A1
20080167657 Greenhalgh Jul 2008 A1
20080177306 Lamborne et al. Jul 2008 A1
20080195096 Frei Aug 2008 A1
20080195210 Mllijasevlo et al. Aug 2008 A1
20080221687 Viker Sep 2008 A1
20080229597 Malandain Sep 2008 A1
20080243251 Stad et al. Oct 2008 A1
20080281346 Greenhalgh et al. Nov 2008 A1
20080281364 Chirico et al. Nov 2008 A1
20090018524 Greenhalgh et al. Jan 2009 A1
20090030423 Puno Jan 2009 A1
20090048678 Saal et al. Feb 2009 A1
20090082872 Beger Mar 2009 A1
20090105775 Mitchell et al. Apr 2009 A1
20100082033 Germain Apr 2010 A1
20100241177 Schaller Sep 2010 A1
20100262242 Chavette Oct 2010 A1
20100298832 Lau Nov 2010 A1
20120239050 Linderman et al. Sep 2012 A1
20120330314 Schaller Dec 2012 A1
20130006232 Pellegrino Jan 2013 A1
Foreign Referenced Citations (43)
Number Date Country
197 10 392 Jul 1999 DE
19710392 Jul 1999 DE
202006005868 Jun 2006 DE
0529275 Mar 1993 EP
0 621 020 Oct 1994 EP
1 157 676 Nov 2001 EP
1157676 Nov 2001 EP
2586183 Feb 1987 FR
2712486 May 1995 FR
2913331 Dec 2008 FR
WO 9304634 Mar 1993 WO
WO 98034552 Aug 1998 WO
WO 0067650 Nov 2000 WO
WO 0067651 Nov 2000 WO
WO 0110316 Feb 2001 WO
WO 0217824 Mar 2002 WO
WO 0230338 Apr 2002 WO
WO 0243628 Jun 2002 WO
WO 0247563 Jun 2002 WO
WO 02071921 Sep 2002 WO
WO 03007854 Jan 2003 WO
WO 03020169 Mar 2003 WO
WO 03022165 Mar 2003 WO
WO 03028587 Apr 2003 WO
WO 03059180 Jul 2003 WO
WO 03101308 Dec 2003 WO
WO 2004034924 Apr 2004 WO
WO2004034924 Apr 2004 WO
WO 2004062505 Jul 2004 WO
WO 2004082526 Sep 2004 WO
WO 2004098420 Nov 2004 WO
WO 2004108022 Dec 2004 WO
WO 2005032433 Apr 2005 WO
WO 2006047645 May 2005 WO
WO 2005051246 Jun 2005 WO
WO 2005081877 Sep 2005 WO
WO 2006047587 May 2006 WO
WO 2006060420 Jun 2006 WO
WO 2006066228 Jun 2006 WO
WO 2006072941 Jul 2006 WO
WO 2006072941 Jul 2006 WO
WO 2007022194 Feb 2007 WO
WO2007067726 Jun 2007 WO
Non-Patent Literature Citations (6)
Entry
US 5,669,928, 09/1997, Aust et al. (withdrawn)
Edeland, H.G., “Some Additional Suggestions for an Intervetebral Disc Prosthesis”, Journal of BioMedical Engr., vol. 7(1), pp. 57-62, Jan. 1985.
U.S. Appl. No. 60/557,246, filed Mar. 29, 2004, entitled: Device and Methods to Reduce and Stabilize Broken Bones.
U.S. Appl. No. 60/689,570, filed Jun. 13, 2005, Inventor Tzony Siegal, entitled: Directional Drilling System.
John A. Carrino, Roxanne Chan and Alexander R. Vaccaro, “Vertebral Augmentation: Vertebroplasty and Kyphoplasty”, Seminars in Roentgenology, vol. 39, No. 1 Jan. 2004, pp. 68-84.
Ajeya P., Joshi, M.D., and Paul A. Glazer, M.D., “Vertebroplasty: Current Concepts and Outlook”, 2003, 9 pages, From: http://www.spineuniverse.com/displayarticle.php/article2076.html.
Related Publications (1)
Number Date Country
20140276471 A1 Sep 2014 US